: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Ovarian Neoplasms

Free Subscription

Articles published in Gynecol Oncol
Retrieve available abstracts of 585 articles:
HTML format

Single Articles

May 2024

GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol. 2024;186:182-190.
PubMed Abstract available

PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al
Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk.
Gynecol Oncol. 2024;187:21-29.
PubMed Abstract available

April 2024

HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al
Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors.
Gynecol Oncol. 2024;186:176-181.
PubMed Abstract available

SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al
"Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.
Gynecol Oncol. 2024;186:170-175.
PubMed Abstract available

CHALIF J, Chambers LM, Yao M, Kuznicki M, et al
Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
Gynecol Oncol. 2024;186:161-169.
PubMed Abstract available

ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al
Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
Gynecol Oncol. 2024;186:144-153.
PubMed Abstract available

EHMANN S, Lam C, Zhou Q, Iasonos A, et al
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;186:104-109.
PubMed Abstract available

GITTO SB, Ihewulezi CJN, Powell DJ Jr
Adoptive T cell therapy for ovarian cancer.
Gynecol Oncol. 2024;186:77-84.
PubMed Abstract available

DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al
Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
Gynecol Oncol. 2024;186:69-76.
PubMed Abstract available

SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al
Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.
Gynecol Oncol. 2024;186:53-60.
PubMed Abstract available

March 2024

HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al
Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
Gynecol Oncol. 2024;186:9-16.
PubMed Abstract available

HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al
Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional study.
Gynecol Oncol. 2024;183:39-46.
PubMed Abstract available

LEVINE BJ
Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics.
Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155.
PubMed

BYRNE M, Sia TY, Fong C, Khurram A, et al
Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144.
PubMed Abstract available

RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;185:186-193.
PubMed Abstract available

NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA
Real world challenges and disparities in the systemic treatment of ovarian cancer.
Gynecol Oncol. 2024;185:180-185.
PubMed Abstract available

CHEN W, Xie J, Gao C, Zhang C, et al
Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.
Gynecol Oncol. 2024;182:108-114.
PubMed Abstract available

February 2024

COSTALES AB, Crane EK, Chambers L, Yao M, et al
Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial.
Gynecol Oncol. 2024;185:143-147.
PubMed Abstract available

RONCOLATO F, King MT, O'Connell RL, Lee YC, et al
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecol Oncol. 2024;185:128-137.
PubMed Abstract available

PENFOUND S, Lukey A, Hodgson J, Hopman WM, et al
Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database.
Gynecol Oncol. 2024;185:116-120.
PubMed Abstract available

SUIDAN RS, Sun CC, Schneider AK, Lu KH, et al
Determination of quality of life-related health utilities for surgical complications in ovarian cancer.
Gynecol Oncol. 2024;185:101-107.
PubMed Abstract available

DISIPIO T, Hartel G, Butow P, Webb PM, et al
Impact of disease recurrence on the supportive care needs of patients with ovarian cancer and their caregivers.
Gynecol Oncol. 2024;185:33-41.
PubMed Abstract available

CHANG C, Cheng YY, Kamlapurkar S, White S, et al
GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15.
Gynecol Oncol. 2024;185:8-16.
PubMed Abstract available

MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043.
PubMed Abstract available

POTHURI B, Han S, Chase DM, Heitz F, et al
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol. 2024;184:168-177.
PubMed Abstract available

TELLES R, Zimmerman MB, Thaker PH, Slavich GM, et al
Rural-urban disparities in psychosocial functioning in epithelial ovarian cancer patients.
Gynecol Oncol. 2024;184:139-145.
PubMed Abstract available

HARI A, Chang J, Villanueva C, Ziogas A, et al
Short-term survival analysis of a risk-adjusted model for ovarian cancer care.
Gynecol Oncol. 2024;184:123-131.
PubMed Abstract available

TAYLOR DD, Gercel-Taylor C, Parker LP
Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
Gynecol Oncol. 2024;181:186.
PubMed

VASTA FM, Cormio G, Cassani C, Bergamini A, et al
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
Gynecol Oncol. 2024;181:28-32.
PubMed Abstract available

January 2024

TUBRIDY EA, Eiva MA, Liu F, Omran DK, et al
CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
Gynecol Oncol. 2024;184:74-82.
PubMed Abstract available

WEHN AK, Qiu P, Lunceford J, Yarunin A, et al
Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
Gynecol Oncol. 2024;184:67-73.
PubMed Abstract available

MOFFAT GT, Kong W, MacKay HJ, McGee J, et al
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
Gynecol Oncol. 2024;184:51-56.
PubMed Abstract available

MUSACCHIO L, Palluzzi E, Di Napoli M, Lauria R, et al
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Gynecol Oncol. 2024;184:24-30.
PubMed Abstract available

BAN D, Housley SN, Matyunina LV, McDonald LD, et al
A personalized probabilistic approach to ovarian cancer diagnostics.
Gynecol Oncol. 2024;182:168-175.
PubMed Abstract available

YANG Q, Peng X, Nian Z, Yuan S, et al
UCHL-3 as a potential biomarker of ovarian cancer.
Gynecol Oncol. 2024;182:156-167.
PubMed Abstract available

WEIGERT M, Cui XL, West-Szymanski D, Yu X, et al
5-Hydroxymethylcytosine signals in serum are a predictor of chemoresistance in high-grade serous ovarian cancer.
Gynecol Oncol. 2024;182:82-90.
PubMed Abstract available

TORTORELLA L, Cappuccio S, Giannarelli D, Nero C, et al
Distribution and prognostic role of BRCA status in elderly ovarian cancer patients.
Gynecol Oncol. 2024;182:57-62.
PubMed Abstract available

LEVINE MD, Wang H, Sriram B, Khan A, et al
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Gynecol Oncol. 2024;182:51-56.
PubMed Abstract available

KAHN RM, Ma X, Gordhandas S, Yeoshoua E, et al
Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State.
Gynecol Oncol. 2024;182:141-147.
PubMed Abstract available

CASANOVA J, Duarte GS, da Costa AG, Catarino A, et al
Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
Gynecol Oncol. 2024;182:99-107.
PubMed Abstract available

CRISTEA MC, Stewart D, Synold T, Ruel N, et al
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRalpha-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Gynecol Oncol. 2024;182:124-131.
PubMed Abstract available

FIFE AJ, Najor AJ, Aspir TB, Haines KE, et al
Reduced healthcare access contributes to delay of care in endometrial cancer.
Gynecol Oncol. 2024;182:115-120.
PubMed Abstract available

KIM SI, Joung JG, Kim YN, Park J, et al
Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
Gynecol Oncol. 2024;182:7-14.
PubMed Abstract available

HANNIBAL CG, Kjaer SK, Galanakis M, Hertzum-Larsen R, et al
History of autoimmune disease and long-term survival of epithelial ovarian cancer: The extreme study.
Gynecol Oncol. 2024;182:1-6.
PubMed Abstract available

GRESSEL GM, Frey MK, Norquist B, Senter L, et al
Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement.
Gynecol Oncol. 2024;181:170-178.
PubMed Abstract available

SZAMRETA EA, Monberg MJ, Desai KD, Li Y, et al
Prognosis and conditional survival among women with newly diagnosed ovarian cancer.
Gynecol Oncol. 2024;180:170-177.
PubMed Abstract available

ALSOMAIRI A, Himayda S, Altelmesani A, Lee YJ, et al
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
Gynecol Oncol. 2024;181:155-161.
PubMed Abstract available

December 2023

WU MF, Cheng XY, Wang DY, Lai YT, et al
Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial.
Gynecol Oncol. 2023;181:125-132.
PubMed Abstract available

PENVOSE KN, Reed SD, Sepulveda JMG, Mastylak A, et al
Development and testing of patient-centered education about hormone replacement therapy for women at high genetic risk of breast and ovarian cancer.
Gynecol Oncol. 2023;181:91-98.
PubMed Abstract available

ALTMANN J, Schmitt W, Bashian N, Sehouli J, et al
A dramatic response to checkpoint inhibitor in a woman with small cell carcinoma of the hypercalcemic type of the ovary.
Gynecol Oncol. 2023;181:99-101.
PubMed Abstract available

CHAN JK, Tian C, Kesterson JP, Lin KY, et al
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
Gynecol Oncol. 2023;181:54-59.
PubMed Abstract available

KIM JH, Kim SI, Park EY, Kim ET, et al
Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
Gynecol Oncol. 2023;181:33-39.
PubMed Abstract available

BENOIT L, Boudebza A, Bentivegna E, Nguyen-Xuan HT, et al
What is the most pertinent definition of malnutrition in epithelial ovarian cancer to assess morbidity and mortality?
Gynecol Oncol. 2023;181:12-19.
PubMed Abstract available

RICHARDSON MT, Barry D, Steinberg JR, Thirunavu V, et al
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials.
Gynecol Oncol. 2023;181:1-7.
PubMed Abstract available

CHAUHAN S, Langstraat CL, Fought AJ, McGree ME, et al
Relationship between frailty and nutrition: Refining predictors of mortality after primary cytoreductive surgery for ovarian cancer.
Gynecol Oncol. 2023;180:126-131.
PubMed Abstract available

YIN X, Zhao S, Zhang M, Xing J, et al
m6A-modified RIPK4 facilitates proliferation and cisplatin resistance in epithelial ovarian cancer.
Gynecol Oncol. 2023;180:99-110.
PubMed Abstract available

KOSKELA H, Li Y, Joutsiniemi T, Muranen T, et al
HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
Gynecol Oncol. 2023;180:91-98.
PubMed Abstract available

CHASE DM, Annavarapu S, Tseng WY, Shi J, et al
Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.
Gynecol Oncol. 2023;180:79-85.
PubMed Abstract available

KAHN RM, Selenica P, Boerner T, Roche KL, et al
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Gynecol Oncol. 2023;180:35-43.
PubMed Abstract available

November 2023

NASIOUDIS D, Gysler S, Latif N, Cory L, et al
Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Gynecol Oncol. 2023;180:1-5.
PubMed Abstract available

PRAISS AM, Hirani R, Zhou Q, Iasonos A, et al
Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2023;179:169-179.
PubMed Abstract available

AGUSTI N, Vidal-Sicart S, Paredes P, Celada-Castro C, et al
Mapping sentinel lymph nodes in early-stage ovarian cancer (MELISA) trial - a further step towards lymphadenectomy replacement.
Gynecol Oncol. 2023;179:145-151.
PubMed Abstract available

DILLEY J, Gentry-Maharaj A, Ryan A, Burnell M, et al
Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Gynecol Oncol. 2023;179:123-130.
PubMed Abstract available

LIM YH, Dagher C, Abu-Rustum NR, Mueller JJ, et al
Oncologic outcomes of robot-assisted laparoscopy versus conventional laparoscopy for the treatment of apparent early-stage endometrioid adenocarcinoma of the uterus.
Gynecol Oncol. 2023;179:152-157.
PubMed Abstract available

BAUMANN KE, Siamakpour-Reihani S, Dottino J, Dai Y, et al
High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.
Gynecol Oncol. 2023;179:97-105.
PubMed Abstract available

BESHAR I, Moon AS, Darji H, Liu C, et al
Aberrant nuclear beta-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study.
Gynecol Oncol. 2023;179:85-90.
PubMed Abstract available

UCCELLA S, Bosco M, Mezzetto L, Garzon S, et al
Major vessel resection for complete cytoreduction in primary advanced and recurrent ovarian malignancies: A case series and systematic review of the literature - pushing the boundaries in oncovascular surgery.
Gynecol Oncol. 2023;179:42-51.
PubMed Abstract available

October 2023

RANDALL LM, O'Malley DM, Monk BJ, Coleman RL, et al
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Gynecol Oncol. 2023;178:161-169.
PubMed Abstract available

LI S, Zhang X, Zhang T, Zhang R, et al
Survival outcomes and establishment of a novel risk stratification system in patients with ovarian yolk sac tumors.
Gynecol Oncol. 2023;178:145-152.
PubMed Abstract available

BRZEZINSKA B, Mysona DP, Richardson KP, Rungruang B, et al
High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy.
Gynecol Oncol. 2023;179:1-8.
PubMed Abstract available

LEDERMANN JA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, et al
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol. 2023;178:119-129.
PubMed Abstract available

IMTERAT M, Gebers G, Heitz F, Schneider S, et al
Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study.
Gynecol Oncol. 2023;178:96-101.
PubMed Abstract available

MCLAUGHLIN HD, Greco P, Straubhar AM, Rolston A, et al
Implementation of routine venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
Gynecol Oncol. 2023;178:89-95.
PubMed Abstract available

KOBEL M, Yang RZ, Kang EY, Al-Shamma Z, et al
Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas.
Gynecol Oncol. 2023;178:80-88.
PubMed Abstract available

NGUYEN NT, Raetz A, Montoya D, Schilling V, et al
Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
Gynecol Oncol. 2023;178:69-79.
PubMed Abstract available

JORGENSEN K, Denham C, Kanbergs A, Wu CF, et al
All-cause and cancer-specific mortality after fertility-sparing surgery for stage IA and IC epithelial ovarian cancer.
Gynecol Oncol. 2023;178:60-68.
PubMed Abstract available

September 2023

MARSH LA, Kim TH, Zhang M, Kubalanza K, et al
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
Gynecol Oncol. 2023;177:173-179.
PubMed Abstract available

WRIGHT AA, Poort H, Tavormina A, Schmiege SJ, et al
Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.
Gynecol Oncol. 2023;177:165-172.
PubMed Abstract available

DUUS AH, Zheng G, Baandrup L, Faber MT, et al
Risk of ovarian cancer after salpingectomy and tubal ligation: Prospects on histology and time since the procedure.
Gynecol Oncol. 2023;177:125-131.
PubMed Abstract available

MOUFARRIJ S, Havrilesky L, Jewell EL
Universal thromboprophylaxis in ovarian cancer patients before and after surgery?
Gynecol Oncol. 2023;176:A1-A2.
PubMed

MCGONIGAL S, Wu R, Grimley E, Turk EG, et al
A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
Gynecol Oncol. 2023;176:139-146.
PubMed Abstract available

LIU Y, Chen J, Lu Z, Chang X, et al
Clinicopathological analysis of patients with molecularly confirmed stage I adult granulosa cell tumors and prediction of recurrence.
Gynecol Oncol. 2023;176:106-114.
PubMed Abstract available

August 2023

NARAYAN P, Ahsan MD, Webster EM, Perez L, et al
Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;177:72-85.
PubMed Abstract available

AO W, Kim HI, Tommarello D, Conrads KA, et al
Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
Gynecol Oncol. 2023;177:60-71.
PubMed Abstract available

MARJON N, Guerra R, Freeman A, Mak J, et al
Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer.
Gynecol Oncol. 2023;177:53-59.
PubMed Abstract available

KIM JH, Park KN, Park EY, Jang MJ, et al
Impact of warm saline irrigation, hyperthermic intraperitoneal chemotherapy on postoperative pain in primary ovarian cancer from the KOV-HIPEC-01 randomized trial.
Gynecol Oncol. 2023;177:32-37.
PubMed Abstract available

HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
Gynecol Oncol. 2023;177:38-45.
PubMed Abstract available

PIGNATA S, Bookman M, Sehouli J, Miller A, et al
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Gynecol Oncol. 2023;177:20-31.
PubMed Abstract available

TAYLOR DD, Gercel-Taylor C, Parker LP
Retraction notice to "Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology Volume 115, Issue 1, October 2009, Pages 112-120].
Gynecol Oncol. 2023;175:193.
PubMed

TAYLOR DD, Gercel-Taylor C
Retraction notice to "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer" [Gynecologic Oncology, Volume 110, Issue 1, July 2008, Pages 13-21].
Gynecol Oncol. 2023;175:192.
PubMed

July 2023

SAITO A, Nishikawa T, Yoshida H, Mizoguchi C, et al
Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Gynecol Oncol. 2023;176:115-121.
PubMed Abstract available

MERCADEL AJ, Sanchez-Covarrubias AP, Medina HN, Pinheiro PS, et al
Intra-racial disaggregation reveals associations between nativity and overall survival in women with endometrial cancer.
Gynecol Oncol. 2023;176:98-105.
PubMed Abstract available

HORVAT N, Causa Andrieu P, Meier A, Ji X, et al
A preoperative nomogram incorporating CT to predict the probability of ovarian clear cell carcinoma.
Gynecol Oncol. 2023;176:90-97.
PubMed Abstract available

DOS SANTOS MV, Holth A, Lindemann K, Staff AC, et al
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma.
Gynecol Oncol. 2023;176:76-81.
PubMed Abstract available

SIA TY, Manning-Geist BL, Ehmann S, Lavery JA, et al
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2023;176:69-75.
PubMed Abstract available

SHAFA A, Watkins AB, McGree ME, Weroha SJ, et al
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
Gynecol Oncol. 2023;176:36-42.
PubMed Abstract available

O'CEARBHAILL RE, Miller A, Soslow RA, Lankes HA, et al
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
Gynecol Oncol. 2023;176:16-24.
PubMed Abstract available

June 2023

TAYLOR KN, Li A, Manuel M, Rimel BJ, et al
The association of black race with receipt of hysterectomy and survival in low-risk endometrial cancer.
Gynecol Oncol. 2023;175:156-162.
PubMed Abstract available

COLOMBO N, Gadducci A, Landoni F, Lorusso D, et al
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol. 2023 Jun 22:S0090-8258(23)00306.
PubMed Abstract available

MORTON M, Haight PJ, Khadraoui W, Backes F, et al
"More than a song and dance": Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok.
Gynecol Oncol. 2023;175:81-87.
PubMed Abstract available

SILBERMAN JN, Bercow AS, Gockley AA, Eisenhauer EL, et al
Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
Gynecol Oncol. 2023;175:60-65.
PubMed Abstract available

POTHURI B, Blank SV, Myers TK, Hines JF, et al
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
Gynecol Oncol. 2023;174:278-287.
PubMed

SMITH AJB, Alvarez R, Heintz J, Simpkins F, et al
Disparities in clinical trial participation in ovarian cancer: A real-world analysis.
Gynecol Oncol. 2023;175:25-31.
PubMed Abstract available

BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Gynecol Oncol. 2023 Jun 2:S0090-8258(23)00299.
PubMed

May 2023

PEIPERT JD, Goble S, Isaacson J, Tang X, et al
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
Gynecol Oncol. 2023;175:1-7.
PubMed Abstract available

EMBABY A, Kutzera J, Geenen JJ, Pluim D, et al
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Gynecol Oncol. 2023;174:239-246.
PubMed Abstract available

PRAISS AM, Miller A, Smith J, Lichtman SM, et al
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Gynecol Oncol. 2023;174:213-223.
PubMed Abstract available

EURICH K, De La Cruz P, Laguna A, Woodman M, et al
Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer.
Gynecol Oncol. 2023;174:200-207.
PubMed Abstract available

HANVIC B, Lecuru F, Vanacker H, Pautier P, et al
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salome study including 469 patients. A TMRG and GINECO group study.
Gynecol Oncol. 2023;174:190-199.
PubMed Abstract available

QIU Y, Zha J, Ma A, Zhou T, et al
Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
Gynecol Oncol. 2023;174:175-181.
PubMed Abstract available

FENG Z, Fu Y, Li R, Li H, et al
Diffusion-weighted magnetic resonance imaging for the pre-operative evaluation of epithelial ovarian cancer patients.
Gynecol Oncol. 2023;174:142-147.
PubMed Abstract available

THOMSON JP, Hollis RL, van Baal J, Ilenkovan N, et al
Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
Gynecol Oncol. 2023;174:157-166.
PubMed Abstract available

WITJES VM, Ligtenberg MJL, Vos JR, Braspenning JCC, et al
The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
Gynecol Oncol. 2023;174:121-128.
PubMed Abstract available

KIM SR, Madariaga A, Hogen L, Vicus D, et al
Safety of fertility sparing management in invasive mucinous ovarian carcinoma.
Gynecol Oncol. 2023;174:129-132.
PubMed Abstract available

MOYETT JM, Howell EP, Broadwater G, Greene M, et al
Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score.
Gynecol Oncol. 2023;174:114-120.
PubMed Abstract available

NEWCOMER MM, Dorayappan KDP, Wagner V, Suarez AA, et al
Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles.
Gynecol Oncol. 2023;173:138-150.
PubMed Abstract available

ALGERA MD, Slangen BFM, van Driel WJ, Wouters MWJM, et al
Textbook outcome as a composite outcome measure to compare hospital performances regarding cytoreductive surgery for ovarian cancer: A nationwide population-based study.
Gynecol Oncol. 2023;174:89-97.
PubMed Abstract available

SIA TY, Gordhandas SB, Birsoy O, Kemel Y, et al
Germline drivers of gynecologic carcinosarcomas.
Gynecol Oncol. 2023;174:34-41.
PubMed Abstract available

SIA TY, Tew WP, Purdy C, Chi DS, et al
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Gynecol Oncol. 2023;173:130-137.
PubMed Abstract available

SAMUEL D, Kwon D, Huang M, Zhao W, et al
Disparities in refusal of surgery for gynecologic cancer.
Gynecol Oncol. 2023;174:1-10.
PubMed Abstract available

BEDNAR EM, Chen M, Walsh MT Jr, Eppolito AL, et al
Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems.
Gynecol Oncol. 2023;172:106-114.
PubMed Abstract available

April 2023

HANDLEY KF, Mehta S, Martin AL, Biswas S, et al
Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma.
Gynecol Oncol. 2023;173:114-121.
PubMed Abstract available

PEREZ L, Webster E, Bull L, Brewer JT, et al
Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature.
Gynecol Oncol. 2023;173:106-113.
PubMed Abstract available

GAUDUCHON T, Kfoury M, Lorusso D, Floquet A, et al
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Gynecol Oncol. 2023;173:98-105.
PubMed Abstract available

CHANG X, Tamauchi S, Yoshida K, Yoshihara M, et al
Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway.
Gynecol Oncol. 2023;173:31-40.
PubMed Abstract available

PIGNATA S, Oza A, Hall G, Pardo B, et al
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Gynecol Oncol. 2023;172:121-129.
PubMed Abstract available

SCHWARTZ ZP, Li AJ, Walsh CS, Rimel BJ, et al
Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
Gynecol Oncol. 2023;173:1-7.
PubMed Abstract available

HERNANDEZ-ZEPEDA ML, Munro EG, Caughey AB, Bruegl AS, et al
Ovarian preservation compared to oophorectomy in premenopausal women with early-stage, low-grade endometrial Cancer: A cost-effectiveness analysis.
Gynecol Oncol. 2023;173:8-14.
PubMed Abstract available

March 2023

BRUCE SF, Wu S, Ribeiro JR, Farrell A, et al
HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Gynecol Oncol. 2023;172:98-105.
PubMed Abstract available

AREND R, Dholakia J, Castro C, Matulonis U, et al
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Gynecol Oncol. 2023;172:82-91.
PubMed Abstract available

MUSACCHIO L, Turinetto M, Arenare L, Bartoletti M, et al
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol. 2023;172:72-77.
PubMed Abstract available

OLULORO A, Temkin SM, Jackson J, Swisher EM, et al
What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women.
Gynecol Oncol. 2023;172:29-35.
PubMed Abstract available

OSANN K, Wenzel L, McKinney C, Wagner L, et al
Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
Gynecol Oncol. 2023;171:151-158.
PubMed Abstract available

BLANC-DURAND F, Yaniz-Galende E, Llop-Guevara A, Genestie C, et al
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Gynecol Oncol. 2023;171:106-113.
PubMed Abstract available

FOTOPOULOU C
Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a "pelvic" surgeon.
Gynecol Oncol. 2023;170:A1-A3.
PubMed

LEE SS, Karpel HC, Oh C, Smith J, et al
Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
Gynecol Oncol. 2023;170:234-240.
PubMed Abstract available

LIU YL, Manning-Geist BL, Knezevic A, Deng L, et al
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Gynecol Oncol. 2023;170:93-101.
PubMed Abstract available

February 2023

HENDRIKSE CSE, Theelen PMM, van der Ploeg P, Westgeest HM, et al
The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;171:83-94.
PubMed Abstract available

TANG H, Fayomi AP, Bai S, Gupta N, et al
Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy.
Gynecol Oncol. 2023;171:49-58.
PubMed Abstract available

LI G, Xu W, Li X, Chen M, et al
Oncogenic SIRT7 inhibits GATA4 transcriptional activity and activates the Wnt signaling pathway in ovarian cancer.
Gynecol Oncol. 2023;171:39-48.
PubMed Abstract available

PRAISS AM, Zhou Q, Iasonos A, Moukarzel L, et al
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
Gynecol Oncol. 2023;171:23-30.
PubMed Abstract available

JORGENSEN K, Melamed A, Wu CF, Nitecki R, et al
Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
Gynecol Oncol. 2023 Feb 10:S0090-8258(23)00017.
PubMed Abstract available

O'MALLEY DM, Ledermann JA, Coleman RL
Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".
Gynecol Oncol. 2023 Feb 9:S0090-8258(23)00049.
PubMed

HERZOG TJ, Pignata S, Ghamande SA, Rubio MJ, et al
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol. 2023;170:300-308.
PubMed Abstract available

WIESER V, Tsibulak I, Reimer DU, Zeimet AG, et al
An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Gynecol Oncol. 2023;170:290-299.
PubMed Abstract available

KOFOED NG, Falconer H, Vanky H, Johansson H, et al
Survival and chance of reversal after intestinal stoma formation during cytoreductive surgery for advanced ovarian cancer; a population-based cohort study.
Gynecol Oncol. 2023;170:259-265.
PubMed Abstract available

GILBERT L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, et al
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gynecol Oncol. 2023;170:241-247.
PubMed Abstract available

January 2023

DAVIDSON TM, Lebreton CL, Hendricksen AEW, Atkinson HJ, et al
Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.
Gynecol Oncol. 2023;170:221-228.
PubMed Abstract available

JAMIESON A, Singh N, Huvila J, Gilks CB, et al
The continuing evolution of endometrial carcinoma molecular classification: Risk stratification within the No Specific Molecular Profile (NSMP) subtype.
Gynecol Oncol. 2023 Jan 26:S0090-8258(22)02019.
PubMed

FERRON G, De Rauglaudre G, Becourt S, Delanoy N, et al
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecol Oncol. 2023;170:186-194.
PubMed Abstract available

HAN C, McNamara B, Bellone S, Harold J, et al
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol. 2023;170:172-178.
PubMed Abstract available

MOUFARRIJ S, Sassine D, Basaran D, Jewell EL, et al
Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review.
Gynecol Oncol. 2023;170:167-171.
PubMed Abstract available

MITRIC C, Salman L, Abrahamyan L, Kim SR, et al
Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2023;170:133-142.
PubMed Abstract available

NAVARRO AS, Gomez CM, Angeles MA, Fuzier R, et al
Open abdominal vacuum pack technique for the management of severe abdominal complications after cytoreductive surgery in ovarian cancer.
Gynecol Oncol. 2023;170:108-113.
PubMed Abstract available

SHIRLEY J, Lambert P, Nachtigal MW, Altman AD, et al
A comparison of synoptic reports and dictated reports to enhance and standardize surgical documentation and quality of care in epithelial ovarian cancer.
Gynecol Oncol. 2023;170:54-58.
PubMed Abstract available

KAHN RM, McMinn E, Yeoshoua E, Boerner T, et al
Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study.
Gynecol Oncol. 2023;170:46-53.
PubMed Abstract available

MAURICIO D, Bellone S, Mutlu L, McNamara B, et al
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol. 2023;170:38-45.
PubMed Abstract available

WANG DF, Shi XW, Zhang C, Zhang J, et al
Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
Gynecol Oncol. 2023;170:25-31.
PubMed Abstract available

KIM JH, Chun SY, Lee DE, Woo YH, et al
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).
Gynecol Oncol. 2023;170:19-24.
PubMed Abstract available

THOMSON CA, Crane TE, Miller A, Gold MA, et al
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.
Gynecol Oncol. 2023;170:11-18.
PubMed Abstract available

December 2022

DINIZ TP, Menezes JN, Goncalves BT, Faloppa CC, et al
Can mismatch repair status be added to sentinel lymph node mapping algorithm in endometrioid endometrial cancer?
Gynecol Oncol. 2022;169:131-136.
PubMed Abstract available

EHMANN S, Shay K, Zhou Q, Iasonos A, et al
Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2022;169:118-124.
PubMed Abstract available

ARMSTRONG DK
AML and MDS associated with PARP inhibitor treatment of ovarian cancer.
Gynecol Oncol. 2022 Dec 15:S0090-8258(22)01961.
PubMed

KAHN R, Filippova O, Gordhandas S, An A, et al
Ten-year conditional probability of survival for patients with ovarian cancer: A new metric tailored to Long-term survivors.
Gynecol Oncol. 2022;169:85-90.
PubMed Abstract available

WOOD N, Morton M, Shah SN, Yao M, et al
Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer.
Gynecol Oncol. 2022;169:55-63.
PubMed Abstract available

NASIOUDIS D, Latif NA, Ko EM, Cory L, et al
Facility level variation in the utilization of neoadjuvant chemotherapy is associated with higher surgical morbidity for patients with advanced stage epithelial ovarian carcinoma.
Gynecol Oncol. 2022;169:41-46.
PubMed Abstract available

MATULONIS UA
The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data.
Gynecol Oncol. 2022;167:401-403.
PubMed

November 2022

CRUM CP, Yoon JY, Feltmate CM
Clinical commentary extra-uterine high-grade serous carcinoma: Two pathways, two preventions?
Gynecol Oncol. 2022;169:1-3.
PubMed

ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680].
Gynecol Oncol. 2022 Nov 28:S0090-8258(22)01924.
PubMed

SHU T, Zhou Z, Bai J, Xiao X, et al
Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
Gynecol Oncol. 2022;168:135-143.
PubMed Abstract available

AKESSON A, Adok C, Dahm-Kahler P
Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study.
Gynecol Oncol. 2022;168:127-134.
PubMed Abstract available

WESTIN SN, Fu S, Tsimberidou A, Piha-Paul S, et al
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Gynecol Oncol. 2022;168:76-82.
PubMed Abstract available

MARK J, Fisher DT, Kim M, Emmons T, et al
Carboplatin enhances lymphocyte-endothelial interactions to promote CD8(+) T cell trafficking into the ovarian tumor microenvironment.
Gynecol Oncol. 2022;168:92-99.
PubMed Abstract available

YANAIHARA N, Yoshino Y, Noguchi D, Tabata J, et al
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
Gynecol Oncol. 2022;168:83-91.
PubMed Abstract available

PHUNG MT, Webb PM, DeFazio A, Fereday S, et al
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.
Gynecol Oncol. 2022;168:68-75.
PubMed Abstract available

PIAO H, Wu M, Qin S, Tang Z, et al
Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis.
Gynecol Oncol. 2022;168:17-22.
PubMed Abstract available

MEAGHER NS, Hamilton P, Milne K, Thornton S, et al
Profiling the immune landscape in mucinous ovarian carcinoma.
Gynecol Oncol. 2022;168:23-31.
PubMed Abstract available

PETERS PN, Moyett JM, Davidson BA, Cantrell S, et al
Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction.
Gynecol Oncol. 2022 Nov 4. pii: S0090-8258(22)01890.
PubMed Abstract available

MUELLER JJ, Rios-Doria E, Park KJ, Broach VA, et al
Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?
Gynecol Oncol. 2022;168:1-7.
PubMed Abstract available

ACKROYD SA, Arguello D, Ramos P, Mahdi H, et al
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
Gynecol Oncol. 2022 Nov 1. pii: S0090-8258(22)01897.
PubMed Abstract available

October 2022

KIM SI, Kim JH, Lee S, Cho H, et al
Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)01887.
PubMed Abstract available

O'MALLEY DM, Oza AM, Lorusso D, Aghajanian C, et al
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol. 2022 Oct 20. pii: S0090-8258(22)00575.
PubMed Abstract available

CHENG A, Rao Q, Liu Y, Huang C, et al
Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
Gynecol Oncol. 2022 Oct 18. pii: S0090-8258(22)01888.
PubMed Abstract available

EBATA T, Yamashita S, Takeshima H, Yoshida H, et al
DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.
Gynecol Oncol. 2022 Oct 14. pii: S0090-8258(22)01881.
PubMed Abstract available

FARLEY JH, Brady WE, O'Malley D, Fujiwara K, et al
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01862.
PubMed Abstract available

CHAN JK, Tian C, Kesterson JP, Richardson MT, et al
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01856.
PubMed Abstract available

GARZON S, Grassi T, Mariani A, Kollikonda S, et al
Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
Gynecol Oncol. 2022 Oct 13. pii: S0090-8258(22)01860.
PubMed Abstract available

ELNAGGAR A, Robins D, Baca Y, Arguello D, et al
Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
Gynecol Oncol. 2022 Oct 10. pii: S0090-8258(22)01850.
PubMed Abstract available

LORUSSO D, Pignata S, Tamberi S, Mangili G, et al
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01851.
PubMed Abstract available

POWELL CB, Laurent C, Garcia C, Hoodfar E, et al
Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
Gynecol Oncol. 2022 Oct 8. pii: S0090-8258(22)01857.
PubMed Abstract available

VON KARTASCHEW AE, Dahm-Kahler P, Rodriguez-Wallberg KA, Holmberg E, et al
Hormone replacement in premenopausal women treated with bilateral oophorectomy for ovarian cancer - a nationwide population-based study.
Gynecol Oncol. 2022 Oct 7. pii: S0090-8258(22)01855.
PubMed Abstract available

September 2022

KONSTANTINOPOULOS PA, Lee JM, Gao B, Miller R, et al
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
Gynecol Oncol. 2022 Sep 30. pii: S0090-8258(22)01839.
PubMed Abstract available

YFAT K, Mariam K, Mario B, Hal H, et al
Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.
Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)00574.
PubMed Abstract available

WICKLINE M, Wolpin S, Cho S, Tomashek H, et al
Usability and acceptability of the electronic self-assessment and care (eSAC) program in advanced ovarian cancer: A mixed methods study.
Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01825.
PubMed Abstract available

GERSHENSON DM, Cobb LP, Westin SN, Zhang Y, et al
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gynecol Oncol. 2022 Sep 19. pii: S0090-8258(22)00591.
PubMed Abstract available

HOU JY, Chapman JS, Kalashnikova E, Pierson W, et al
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
Gynecol Oncol. 2022 Sep 15. pii: S0090-8258(22)00590.
PubMed Abstract available

YU S, Yang R, Xu T, Li X, et al
Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00589.
PubMed Abstract available

RUSH SK, Lees BF, Huang DS, Peterson MF, et al
Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes.
Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00577.
PubMed Abstract available

LI N, Zhu X, Nian W, Li Y, et al
Blood-based DNA methylation profiling for the detection of ovarian cancer.
Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00480.
PubMed Abstract available

VREDE SW, Hulsman AMC, Reijnen C, Van de Vijver K, et al
The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification.
Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00570.
PubMed Abstract available

VAN STEIN RM, Engbersen MP, Stolk T, Lopez-Yurda M, et al
Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer.
Gynecol Oncol. 2022 Sep 7. pii: S0090-8258(22)00576.
PubMed Abstract available

MENZIES AV, Usher EC, Hsu FC, Levine EA, et al
HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
Gynecol Oncol. 2022 Sep 6. pii: S0090-8258(22)00569.
PubMed Abstract available

LAGO V, Segarra-Vidal B, Cappucio S, Angeles MA, et al
OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery.
Gynecol Oncol. 2022 Sep 1. pii: S0090-8258(22)00542.
PubMed Abstract available

VAN DEN HEERIK ASVM, Aiyer KTS, Stelloo E, Jurgenliemk-Schulz IM, et al
Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
Gynecol Oncol. 2022;166:530-537.
PubMed Abstract available

August 2022

POZZAR RA, Xiong N, Hong F, Wright AA, et al
How does patient-centered communication in ovarian cancer care enhance patient well-being? A mixed methods study.
Gynecol Oncol. 2022 Aug 31. pii: S0090-8258(22)00573.
PubMed Abstract available

BUI A, Gehrig PA, Ghamande S, Rungruang BJ, et al
Clinical calculator redefines prognosis for high-risk early-stage ovarian cancers and potential to guide treatment in the adjuvant setting.
Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00551.
PubMed Abstract available

MADARIAGA A, Mitchell SA, Pittman T, Wang L, et al
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovaria
Gynecol Oncol. 2022 Aug 30. pii: S0090-8258(22)00544.
PubMed Abstract available

BOKKERS K, Frederix GWJ, Velthuizen ME, van der Aa M, et al
Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
Gynecol Oncol. 2022 Aug 25. pii: S0090-8258(22)00550.
PubMed Abstract available

THOMAS QD, Boussere A, Classe JM, Pomel C, et al
Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00543.
PubMed Abstract available

MOSS KM, Mishra GD, Krejany EO, Hickey M, et al
What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2022 Aug 3. pii: S0090-8258(22)00513.
PubMed Abstract available

KUMAR A, Wang C, Sheedy SP, McCauley BM, et al
Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00492.
PubMed Abstract available

SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
Corrigendum to "Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer" [Gynecologic Oncology, Volume 165, Issue 2, May 2022, Pages 270-280].
Gynecol Oncol. 2022;166:370-371.
PubMed

July 2022

HOARE JI, Hockings H, Saxena J, Silva VL, et al
A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00511.
PubMed Abstract available

JOLY F, Fabbro M, Berton D, Lequesne J, et al
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00426.
PubMed Abstract available

LIANG MI, Simons JL, Herbey I, Wall JA, et al
Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00493.
PubMed Abstract available

KIM SI, Kim JH, Noh JJ, Kim SH, et al
Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00483.
PubMed Abstract available

CHASE DM, Marin MR, Backes F, Han S, et al
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
Gynecol Oncol. 2022 Jul 15. pii: S0090-8258(22)00432.
PubMed Abstract available

HARE CJ, Crangle C, McGarragle K, Ferguson SE, et al
Change in cancer-related fatigue over time predict health-related quality of life in ovarian cancer patients.
Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00433.
PubMed Abstract available

PITIYARACHCHI O, Friedlander M, Java JJ, Chan JK, et al
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (>/=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemothera
Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00436.
PubMed Abstract available

PIEDIMONTE S, Bernardini MQ, Ding A, Laframboise S, et al
Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
Gynecol Oncol. 2022 Jul 9. pii: S0090-8258(22)00430.
PubMed Abstract available

CADOO K, Simpkins F, Mathews C, Liu YL, et al
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Gynecol Oncol. 2022 Jul 5. pii: S0090-8258(22)00421.
PubMed Abstract available

TSENG JH, Bristow RE
Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles.
Gynecol Oncol. 2022;166:5-7.
PubMed

HANDLEY KF, Sood AK, Molin GZD, Westin SN, et al
Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
Gynecol Oncol. 2022;166:50-56.
PubMed Abstract available

O'CEARBHAILL RE, Perez-Fidalgo JA, Monk BJ, Tusquets I, et al
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Gynecol Oncol. 2022;166:36-43.
PubMed Abstract available

June 2022

WALL JA, Lipking K, Smith HJ, Huh WK, et al
Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
PubMed Abstract available

DICKEN BJ, Billmire DF, Rich B, Hazard FK, et al
Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group.
Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00417.
PubMed Abstract available

KEUNECKE C, Kulbe H, Dreher F, Taube ET, et al
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00414.
PubMed Abstract available

KIM NR, Lee AJ, Yang EJ, So KA, et al
Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis.
Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00404.
PubMed Abstract available

CAMPBELL R, Costa DSJ, Stockler MR, Lee YC, et al
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecol Oncol. 2022 Jun 16. pii: S0090-8258(22)00335.
PubMed Abstract available

HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Gynecol Oncol. 2022 Jun 8. pii: S0090-8258(22)00331.
PubMed Abstract available

LOF P, van de Vrie R, Korse CM, van Gent MDJM, et al
Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?
Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00336.
PubMed Abstract available

NASIOUDIS D, Mastroyannis SA, Ko EM, Haggerty AF, et al
Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.
Gynecol Oncol. 2022 Jun 3. pii: S0090-8258(22)00314.
PubMed Abstract available

GERSHENSON DM, Sun CC, Westin SN, Eyada M, et al
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
Gynecol Oncol. 2022;165:560-567.
PubMed Abstract available

HOU X, Zhai Y, Hu K, Liu CJ, et al
Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
Gynecol Oncol. 2022;165:552-559.
PubMed Abstract available

May 2022

BROEKMAN KE, van der Aa MA, Nijman HW, Jalving M, et al
End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis.
Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00258.
PubMed Abstract available

TYMON-ROSARIO JR, Manara P, Manavella DD, Bellone S, et al
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Gynecol Oncol. 2022 May 19. pii: S0090-8258(22)00305.
PubMed Abstract available

WANG CC, Al-Rubaye R, Tran V, Montemorano L, et al
Mechanical and oral antibiotic bowel preparation in ovarian cancer debulking: Are we lowering or just trading surgical complications?
Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00307.
PubMed Abstract available

HINCHCLIFF E, Westin SN, Herzog TJ
State of the science: Contemporary front-line treatment of advanced ovarian cancer.
Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00275.
PubMed

ANGELES MA, Hernandez A, Perez-Benavente A, Cabarrou B, et al
The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.
Gynecol Oncol. 2022 May 11. pii: S0090-8258(22)00278.
PubMed Abstract available

GUIDA F, Dioun S, Fagotti A, Melamed A, et al
Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.
Gynecol Oncol. 2022 May 9. pii: S0090-8258(22)00218.
PubMed Abstract available

April 2022

WILHITE AM, Baca Y, Xiu J, Paladugu R, et al
Molecular profiles of endometrial cancer tumors among Black patients.
Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00255.
PubMed Abstract available

FU Z, Taylor S, Modugno F
Lifetime ovulations and epithelial ovarian cancer risk and survival: A systematic review and meta-analysis.
Gynecol Oncol. 2022 Apr 23. pii: S0090-8258(22)00214.
PubMed Abstract available

WANG D, Jia S, Jia C, Cao D, et al
Oncological and reproductive outcomes after fertility-sparing surgery in patients with seromucinous borderline ovarian tumor: Results of a large retrospective study.
Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00215.
PubMed Abstract available

LOF P, Retel VP, Algera MD, van Gent MDJM, et al
Clinical implementation of routine diagnostic laparoscopy to guide initial treatment in patients with advanced-stage epithelial ovarian cancer in Dutch clinical practice: Evaluation of support and a budget impact analysis.
Gynecol Oncol. 2022 Apr 9. pii: S0090-8258(22)00210.
PubMed Abstract available

GERSEKOWSKI K, Delahunty R, Alsop K, Goode EL, et al
Germline BRCA variants, lifestyle and ovarian cancer survival.
Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00202.
PubMed Abstract available

NORPPA N, Staff S, Helminen M, Auranen A, et al
Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.
Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00205.
PubMed Abstract available

BIZZARRI N, Marchetti C, Conte C, Loverro M, et al
The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00206.
PubMed Abstract available

HENNO S, Jeanne C, Rouge TM, Genestie C, et al
Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).
Gynecol Oncol. 2022 Apr 4. pii: S0090-8258(22)00201.
PubMed Abstract available

VAN DER PLOEG P, Uittenboogaard A, Bosch SL, van Diest PJ, et al
Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium.
Gynecol Oncol. 2022;165:114-120.
PubMed Abstract available

March 2022

MARINELLI LM, Kisiel JB, Slettedahl SW, Mahoney DW, et al
Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00200.
PubMed Abstract available

SIMILA-MAARALA J, Soovares P, Pasanen A, Ahvenainen T, et al
TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00198.
PubMed Abstract available

LIM H, In Shim J, Park SJ, Noh J, et al
Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
Gynecol Oncol. 2022 Mar 30. pii: S0090-8258(22)00196.
PubMed Abstract available

STELTEN S, van Lonkhuijzen LRCW, Hartman YAW, van Driel WJ, et al
Experiences, adherence and satisfaction with a combined exercise and dietary intervention for patients with ovarian cancer undergoing chemotherapy: A mixed-methods study.
Gynecol Oncol. 2022 Mar 22. pii: S0090-8258(22)00182.
PubMed Abstract available

SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
Gynecol Oncol. 2022 Mar 16. pii: S0090-8258(22)00176.
PubMed Abstract available

MOUKARZEL LA, Ferrando L, Dopeso H, Stylianou A, et al
Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
Gynecol Oncol. 2022 Mar 12. pii: S0090-8258(22)00141.
PubMed Abstract available

HAWKINS GM, Burkett WC, McCoy AN, Nichols HB, et al
Differences in the microbial profiles of early stage endometrial cancers between Black and White women.
Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00142.
PubMed Abstract available

CHALIF J, Yao M, Gruner M, Kuznicki M, et al
Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00065.
PubMed Abstract available

SCHNARR KL, Seow H, Pond GR, Helpman L, et al
The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers.
Gynecol Oncol. 2022 Mar 2. pii: S0090-8258(22)00129.
PubMed Abstract available

February 2022

GOINS EC, Weber JM, Truong T, Moss HA, et al
Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database.
Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00069.
PubMed Abstract available

FALCONE F, Malzoni M, Carnelli M, Cormio G, et al
Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00128.
PubMed Abstract available

MATSUO K, Chen L, Guo XM, Roman LD, et al
Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study.
Gynecol Oncol. 2022 Feb 25. pii: S0090-8258(22)00126.
PubMed Abstract available

MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00124.
PubMed

KIM YN, Kim JC, Chung YS, Park J, et al
Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study.
Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00091.
PubMed Abstract available

LAFARGUE CJ, Handley KF, Fleming ND, Nick AM, et al
Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00090.
PubMed Abstract available

ALGERA MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, et al
Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00123.
PubMed Abstract available

VANDERSTICHELE A, Loverix L, Busschaert P, Van Nieuwenhuysen E, et al
Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
Gynecol Oncol. 2022 Feb 14. pii: S0090-8258(22)00073.
PubMed Abstract available

PARK J, Kim SI, Jeong SY, Kim Y, et al
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Gynecol Oncol. 2022 Feb 10. pii: S0090-8258(22)00086.
PubMed Abstract available

WAGAR MK, Mojdehbakhsh RP, Godecker A, Rice LW, et al
Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
Gynecol Oncol. 2022 Feb 7. pii: S0090-8258(22)00071.
PubMed Abstract available

LEMON LS, Orr B, Modugno F, Buckanovich RJ, et al
Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?
Gynecol Oncol. 2022 Feb 6. pii: S0090-8258(22)00049.
PubMed Abstract available

JOLY F, Fabbro M, Follana P, Lequesne J, et al
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Gynecol Oncol. 2022 Feb 2. pii: S0090-8258(22)00048.
PubMed Abstract available

January 2022

TRILLSCH F, Mahner S, Ataseven B, Asher R, et al
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00050.
PubMed Abstract available

RAIMONDO D, Raffone A, Zakhari A, Maletta M, et al
The impact of hysterectomy on oncological outcomes in patients with borderline ovarian tumors: A systematic review and meta-analysis.
Gynecol Oncol. 2022 Jan 25. pii: S0090-8258(22)00046.
PubMed Abstract available

COLOMBO N, Tomao F, Benedetti Panici P, Nicoletto MO, et al
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00023.
PubMed Abstract available

XIA YY, Gronwald J, Karlan B, Lubinski J, et al
Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00022.
PubMed Abstract available

BOUCHARD-FORTIER G, Gien LT, Sutradhar R, Chan WC, et al
Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study.
Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00004.
PubMed Abstract available

POVEDA A, Lheureux S, Colombo N, Cibula D, et al
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01693.
PubMed Abstract available

ZHANG J, Yu S, Li Q, Wang Q, et al
Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer.
Gynecol Oncol. 2022 Jan 15. pii: S0090-8258(22)00018.
PubMed Abstract available

FIEGL H, Hagenbuchner J, Kyvelidou C, Seeber B, et al
Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids.
Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00009.
PubMed Abstract available

WEINMANN S, Phillips S, Sweet K, Cosgrove CM, et al
Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01695.
PubMed Abstract available

LIN DI, Fine A, Danziger NA, Huang RSP, et al
Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01698.
PubMed Abstract available

SHALOWITZ DI, DeMari JA
Defining the essential role of the gynecologic oncologist in rural ovarian cancer care delivery.
Gynecol Oncol. 2022;164:1-2.
PubMed

December 2021

CORRIGAN KL, Yoder A, De B, Lin L, et al
Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis.
Gynecol Oncol. 2021 Dec 30. pii: S0090-8258(21)01690.
PubMed Abstract available

BEESLEY VL, Ross TL, King MT, Campbell R, et al
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01632.
PubMed Abstract available

REIJNTJES B, van Suijlichem M, Woolderink JM, Bongers MY, et al
Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial.
Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01676.
PubMed Abstract available

PHILP L, Alimena S, Ferris W, Saini A, et al
Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer.
Gynecol Oncol. 2021 Dec 22. pii: S0090-8258(21)01674.
PubMed Abstract available

HARTER P, Mouret-Reynier MA, Pignata S, Cropet C, et al
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01673.
PubMed Abstract available

MONK BJ, Smith G, Lima J, Long GH, et al
Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01634.
PubMed Abstract available

KO EM, Bekelman JE, Hicks-Courant K, Brensinger CM, et al
Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01627.
PubMed Abstract available

AGHAJANIAN C, Swisher EM, Okamoto A, Steffensen KD, et al
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Gynecol Oncol. 2021 Dec 17. pii: S0090-8258(21)01638.
PubMed Abstract available

HA HI, Park EY, Eoh KJ, Lee YJ, et al
Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
Gynecol Oncol. 2021 Dec 16. pii: S0090-8258(21)01639.
PubMed Abstract available

SWIFT BE, Maeda A, Bouchard-Fortier G
Low incidence of venous thromboembolism after gynecologic oncology surgery: Who is at greatest risk?
Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01637.
PubMed Abstract available

ZHOU ZN, Chen L, Melamed A, St Clair CM, et al
Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer.
Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01631.
PubMed Abstract available

SWISHER EM, Aghajanian C, O'Malley DM, Fleming GF, et al
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Gynecol Oncol. 2021 Dec 11. pii: S0090-8258(21)01630.
PubMed Abstract available

HODGSON DR, Brown JS, Dearden SP, Lai Z, et al
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
Gynecol Oncol. 2021;163:563-568.
PubMed Abstract available

November 2021

JOHN CS, Fong A, Alban R, Gillen J, et al
Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01521.
PubMed Abstract available

DUPONT NC, Enserro D, Brady MF, Moxley K, et al
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Gynecol Oncol. 2021 Nov 29. pii: S0090-8258(21)01607.
PubMed Abstract available

MOYA-ALARCON C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, et al
Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01604.
PubMed Abstract available

CIANCI S, Fedele C, Vizzielli G, Pasciuto T, et al
Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGON.
Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01605.
PubMed Abstract available

RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693].
Gynecol Oncol. 2021 Nov 19. pii: S0090-8258(21)01601.
PubMed

MATUSZEWSKA K, Ten Kortenaar S, Pereira M, Santry LA, et al
Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01599.
PubMed Abstract available

MATTHEWS BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, et al
Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer.
Gynecol Oncol. 2021 Nov 13. pii: S0090-8258(21)01553.
PubMed Abstract available

WEEKS KS, Lynch CF, West M, Carnahan R, et al
Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.
Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01555.
PubMed Abstract available

KHOJA L, Weber RP, Webb PM, Jordan SJ, et al
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01552.
PubMed Abstract available

MANNING-GEIST BL, Gordhandas SB, Giri DD, Iasonos A, et al
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01551.
PubMed Abstract available

FABER MT, Horsbol TA, Baandrup L, Dalton SO, et al
Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996-2017.
Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01554.
PubMed Abstract available

October 2021

ROCCONI RP, Wilhite AM, Schambeau L, Scalici J, et al
A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01527.
PubMed Abstract available

CALO CA, Smith BQ, Dorayappan KDP, Saini U, et al
Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01520.
PubMed Abstract available

GOLDBERG RM, Kim SR, Fazelzad R, Li X, et al
Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01524.
PubMed Abstract available

EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01525.
PubMed Abstract available

SOOVARES P, Pasanen A, Simila-Maarala J, Butzow R, et al
Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.
Gynecol Oncol. 2021 Oct 25. pii: S0090-8258(21)01522.
PubMed Abstract available

WALTER A, Rocconi RP, Monk BJ, Herzog TJ, et al
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01422.
PubMed Abstract available

WITJES VM, van Bommel MHD, Ligtenberg MJL, Vos JR, et al
Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01516.
PubMed Abstract available

TREDAN O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01402.
PubMed Abstract available

HARRISON R, Zighelboim I, Cloven NG, Marcus JZ, et al
Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01452.
PubMed

MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01513.
PubMed Abstract available

GERNIER F, Gompel A, Rousset-Jablonski C, Kalbacher E, et al
Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.
Gynecol Oncol. 2021 Oct 11. pii: S0090-8258(21)01419.
PubMed Abstract available

KONECNY GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, et al
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
Gynecol Oncol. 2021 Oct 9. pii: S0090-8258(21)01413.
PubMed Abstract available

LIU J, Burris H, Wang JS, Barroilhet L, et al
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Gynecol Oncol. 2021 Oct 6. pii: S0090-8258(21)01403.
PubMed Abstract available

SHAH PD, Wethington SL, Pagan C, Latif N, et al
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Gynecol Oncol. 2021 Oct 4. pii: S0090-8258(21)01322.
PubMed Abstract available

TEWARIE NMSB, van Driel WJ, van Ham M, Wouters MW, et al
Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01392.
PubMed

CLAIR KH, Bristow RE
The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.
Gynecol Oncol. 2021;163:3-4.
PubMed

ALHILLI MM, Rybicki L, Carr C, Yao M, et al
Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01377.
PubMed Abstract available

September 2021

SWISHER EM, Kristeleit RS, Oza AM, Tinker AV, et al
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01329.
PubMed Abstract available

HA HI, Cho SH, Lim J, Lee YJ, et al
Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01383.
PubMed Abstract available

AZZALINI E, Barbazza R, Stanta G, Giorda G, et al
Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01382.
PubMed Abstract available

LI JY, Park HS, Huang GS, Young MR, et al
Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01391.
PubMed Abstract available

BRYK S, Katuwal S, Haltia UM, Tapper J, et al
Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study.
Gynecol Oncol. 2021 Sep 28. pii: S0090-8258(21)01381.
PubMed Abstract available

ATASEVEN B, Tripon D, Schwameis R, Harter P, et al
Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01335.
PubMed Abstract available

RESHKO LB, Gaskins JT, Rattani A, Farley AA, et al
Patterns of care and outcomes of radiotherapy or hormone therapy in patients with medically inoperable endometrial adenocarcinoma.
Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01375.
PubMed Abstract available

LEE SJ, Kim YH, Lee MY, Ko HS, et al
Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women.
Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01376.
PubMed Abstract available

HUANG T, Townsend MK, Dood RL, Sood AK, et al
Antihypertensive medication use and ovarian cancer survival.
Gynecol Oncol. 2021 Sep 20. pii: S0090-8258(21)01378.
PubMed Abstract available

WENZEL L, Huang HQ, Cella D, McKinney CO, et al
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
Gynecol Oncol. 2021 Sep 18. pii: S0090-8258(21)01326.
PubMed Abstract available

GAILLARD S, Oaknin A, Ray-Coquard I, Vergote I, et al
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
Gynecol Oncol. 2021 Sep 11. pii: S0090-8258(21)01330.
PubMed Abstract available

MOSS HA, Chen L, Hershman DL, Davidson B, et al
Adherence to PARP inhibitor therapy among women with ovarian cancer.
Gynecol Oncol. 2021 Sep 9. pii: S0090-8258(21)01323.
PubMed Abstract available

WANG Z, Guo E, Yang B, Xiao R, et al
Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer.
Gynecol Oncol. 2021 Sep 7. pii: S0090-8258(21)01327.
PubMed Abstract available

WERNER B, Yuwono N, Duggan J, Liu D, et al
Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
Gynecol Oncol. 2021;162:720-727.
PubMed Abstract available

CAMPBELL R, King MT, Ross TL, Cohen PA, et al
Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
Gynecol Oncol. 2021 Sep 1. pii: S0090-8258(21)01320.
PubMed Abstract available

August 2021

FUH KC, Bookman MA, Liu JF, Coleman RL, et al
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
Gynecol Oncol. 2021 Aug 30. pii: S0090-8258(21)01318.
PubMed Abstract available

STEENBEEK MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, et al
Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
Gynecol Oncol. 2021 Aug 26. pii: S0090-8258(21)01317.
PubMed Abstract available

POZZAR RA, Xiong N, Hong F, Wright AA, et al
Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer.
Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)00652.
PubMed Abstract available

EBINA Y, Yamagami W, Kobayashi Y, Tabata T, et al
Clinicopathological characteristics and prognostic factors of ovarian granulosa cell tumors: A JSGO-JSOG joint study.
Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)01310.
PubMed Abstract available

TAMURA R, Yoshihara K, Matsuo K, Yachida N, et al
Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01307.
PubMed Abstract available

SOMASEGAR S, Weiss AS, Norquist BM, Khasnavis N, et al
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01315.
PubMed Abstract available

D'AMORA P, Silva IDCG, Tewari KS, Bristow RE, et al
Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis.
Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)00646.
PubMed Abstract available

D'ALESSANDRIS N, Travaglino A, Santoro A, Arciuolo D, et al
TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)01309.
PubMed Abstract available

COWAN M, Swetzig WM, Adorno-Cruz V, Pineda MJ, et al
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
Gynecol Oncol. 2021 Aug 18. pii: S0090-8258(21)00650.
PubMed Abstract available

BANERJEE SN, Tang M, O'Connell RL, Sjoquist K, et al
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Gynecol Oncol. 2021 Aug 16. pii: S0090-8258(21)00586.
PubMed Abstract available

LUTGENDORF SK, Ramirez E, Schrepf A, Valentine MC, et al
Rural residence is related to shorter survival in epithelial ovarian cancer patients.
Gynecol Oncol. 2021 Aug 13. pii: S0090-8258(21)00601.
PubMed Abstract available

PARK M, Lim J, Lee JA, Park HJ, et al
Incidence and outcomes of malignant ovarian germ cell tumors in Korea, 1999-2017.
Gynecol Oncol. 2021 Aug 12. pii: S0090-8258(21)00645.
PubMed Abstract available

WETHINGTON SL, Wahner-Hendrickson AE, Swisher EM, Kaufmann SH, et al
PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
Gynecol Oncol. 2021 Aug 11. pii: S0090-8258(21)00647.
PubMed

WENTZENSEN N, O'Brien KM
Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence.
Gynecol Oncol. 2021 Aug 5. pii: S0090-8258(21)00598.
PubMed Abstract available

COLOMBO N, Moore K, Scambia G, Oaknin A, et al
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
Gynecol Oncol. 2021 Aug 2. pii: S0090-8258(21)00578.
PubMed Abstract available

SALANI R, Liu JF
The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstracts.
Gynecol Oncol. 2021;162:245-248.
PubMed

GROENEWEG JW, Roze JF, Peters EDJ, Sereno F, et al
FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Gynecol Oncol. 2021;162:413-420.
PubMed Abstract available

July 2021

BANTIE L, Tadesse S, Likisa J, Yu M, et al
Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838].
Gynecol Oncol. 2021 Jul 30. pii: S0090-8258(21)00580.
PubMed

VILLANUEVA C, Chang J, Ziogas A, Bristow RE, et al
Ambient air pollution and ovarian cancer survival in California.
Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00602.
PubMed Abstract available

NANEZ A, Stram DA, Garcia C, Powell CB, et al
Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00600.
PubMed Abstract available

LAZURKO C, Clark M, Pulman K, Lennox G, et al
Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
Gynecol Oncol. 2021 Jul 26. pii: S0090-8258(21)00589.
PubMed Abstract available

BASARAN D, Boerner T, Suhner J, Sassine D, et al
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00592.
PubMed Abstract available

MARCHETTI C, Rosati A, De Felice F, Boccia SM, et al
Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00587.
PubMed Abstract available

EOH KJ, Park EY, Chang YJ, Ha HI, et al
The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
Gynecol Oncol. 2021 Jul 22. pii: S0090-8258(21)00590.
PubMed Abstract available

MOSS HA, Perhanidis JA, Havrilesky LJ, Secord AA, et al
Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
Gynecol Oncol. 2021 Jul 20. pii: S0090-8258(21)00588.
PubMed Abstract available

CIBULA D, Rob L, Mallmann P, Knapp P, et al
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00533.
PubMed Abstract available

DE NONNEVILLE A, Zemmour C, Frank S, Joly F, et al
Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00581.
PubMed Abstract available

ZENG H, Chen L, Zhang M, Luo Y, et al
Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00577.
PubMed Abstract available

RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00531.
PubMed Abstract available

GHONIEM K, Larish AM, Dinoi G, Zhou XC, et al
Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study.
Gynecol Oncol. 2021 Jul 14. pii: S0090-8258(21)00526.
PubMed Abstract available

KURODA Y, Chiyoda T, Kawaida M, Nakamura K, et al
ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00536.
PubMed Abstract available

BACKES FJ, Wei L, Chen M, Hill K, et al
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00528.
PubMed Abstract available

HERMENS M, van Altena AM, Bulten J, van Vliet HAAM, et al
Increased incidence of ovarian cancer in both endometriosis and adenomyosis.
Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00535.
PubMed Abstract available

HUFFMAN DL, Jayakrishnan TT, Shankar K, Peterson CE, et al
Disparities in ovarian cancer treatment and overall survival according to race: An update.
Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00541.
PubMed Abstract available

VAN DER PLOEG P, Uittenboogaard A, Thijs AMJ, Westgeest HM, et al
The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00538.
PubMed Abstract available

KIM SR, Malcolmson J, Li X, Bernardini MQ, et al
The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00540.
PubMed Abstract available

GRUNER M, Chambers LM, Yao M, Chichura A, et al
Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00530.
PubMed Abstract available

SULLIVAN MW, Philp L, Kanbergs AN, Safdar N, et al
Lymph node assessment at the time of hysterectomy has limited clinical utility for patients with pre-cancerous endometrial lesions.
Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00534.
PubMed Abstract available

GADDUCCI A, Multinu F, Cosio S, Carinelli S, et al
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00529.
PubMed Abstract available

KRASNER CN, Campos SM, Young CL, Chadda KR, et al
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Gynecol Oncol. 2021 Jul 6. pii: S0090-8258(21)00532.
PubMed Abstract available

HILLMAN RT, Lin DI, Lawson B, Gershenson DM, et al
Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
Gynecol Oncol. 2021 Jul 5. pii: S0090-8258(21)00518.
PubMed Abstract available

June 2021

BENOIT L DR, Zerbib J Dr, Koual M Dr, Nguyen-Xuan HT Dr, et al
What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00521.
PubMed Abstract available

SAFRA T, Waissengrin B, Gerber D, Bernstein-Molho R, et al
Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00489.
PubMed Abstract available

WAGAR MK, Sobecki JN, Chandereng T, Hartenbach EM, et al
Postoperative venous thromboembolism in gynecologic oncology patients undergoing minimally invasive surgery: Does modality matter?
Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00491.
PubMed Abstract available

BALDEWPERSAD TEWARIE NMS, van Driel WJ, van Ham M, Wouters MW, et al
Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00436.
PubMed Abstract available

JIANG C, Li Z
Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00483.
PubMed Abstract available

FAN Y, Zhang YF, Wang MY, Mu Y, et al
Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis.
Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00439.
PubMed Abstract available

HICKEY M, Moss KM, Krejany EO, Wrede CD, et al
What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12months after premenopausal risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2021 Jun 8. pii: S0090-8258(21)00442.
PubMed Abstract available

VAN DER ZANDEN V, van Soolingen NJ, Viddeleer AR, Trum JW, et al
Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer.
Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00445.
PubMed Abstract available

AGHAJANIAN C, Bookman MA, Fleming GF, Swisher EM, et al
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00437.
PubMed Abstract available

CASPER AC, Parsons MW, Chipman J, Burt LM Jr, et al
Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00440.
PubMed Abstract available

LI S, Bercow AS, Falzone M, Kalyanaraman R, et al
Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00438.
PubMed Abstract available

HANLEY GE, Kaur P, Berchuck A, Chase A, et al
Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00427.
PubMed Abstract available

ALVAREZ SECORD A, O'Malley DM, Sood AK, Westin SN, et al
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00424.
PubMed Abstract available

SHARMA A, Singh M, Chauhan R, Malik PS, et al
Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00431.
PubMed Abstract available

SUE-A-QUAN R, Patel PG, Shakfa N, Nyi MN, et al
Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00406.
PubMed Abstract available

May 2021

FRANGOU E, Bertelli G, Love S, Mackean MJ, et al
OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00430.
PubMed Abstract available

HAVRILESKY LJ, Scott AL, Davidson BA, Secord AA, et al
The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00428.
PubMed Abstract available

DE JONG JM, Hoogendam JP, Braat AJAT, Zweemer RP, et al
The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review.
Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00423.
PubMed Abstract available

MANNING-GEIST BL, Chi DS, Long Roche K, Zivanovic O, et al
Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Gynecol Oncol. 2021 May 25. pii: S0090-8258(21)00421.
PubMed Abstract available

LIN J, Sharaf RN, Saganty R, Ahsan D, et al
Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00407.
PubMed Abstract available

HEMMINGSEN CH, Kjaer SK, Bennetsen AKK, Dehlendorff C, et al
The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00404.
PubMed Abstract available

KIM SI, Yoon S, Kim TM, Cho JY, et al
Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique.
Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00363.
PubMed Abstract available

TRAN DT, Vo VK, Le MT, Chuang L, et al
Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.
Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00360.
PubMed Abstract available

CABRERA S, Barahona-Orpinell M, Almansa-Gonzalez C, Padilla-Iserte P, et al
Combined use of ICG and technetium does not improve sentinel lymph node detection in endometrial cancer: Results of the COMBITEC study.
Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00361.
PubMed Abstract available

HICKEY M, Moss KM, Mishra GD, Krejany EO, et al
What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
Gynecol Oncol. 2021 May 7. pii: S0090-8258(21)00358.
PubMed Abstract available

CAO L, Wei M, Liu Y, Fu J, et al
Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses.
Gynecol Oncol. 2021 May 6. pii: S0090-8258(21)00351.
PubMed Abstract available

CHAM S, Huang Y, Melamed A, Worley MJ Jr, et al
Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
Gynecol Oncol. 2021 May 5. pii: S0090-8258(21)00352.
PubMed Abstract available

GAMBLE CR, Huang Y, Wright JD, Hou JY, et al
Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance.
Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00345.
PubMed Abstract available

SIMS TT, Boruta DM
Sentinel lymph node isolated tumor cells in early staged endometrioid endometrial cancer: Utility or futility?
Gynecol Oncol. 2021;161:331-332.
PubMed

GILLEN J, Miller A, Bell-McGuinn KM, Schilder RJ, et al
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gynecol Oncol. 2021;161:512-515.
PubMed Abstract available

April 2021

MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer.
Gynecol Oncol. 2021 Apr 27. pii: S0090-8258(21)00344.
PubMed Abstract available

GIANNONE G, Scotto G, Katsaros D, De Giorgi U, et al
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
Gynecol Oncol. 2021 Apr 22. pii: S0090-8258(21)00328.
PubMed Abstract available

THUSGAARD CF, Korsholm M, Koldby KM, Kruse TA, et al
Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review.
Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00330.
PubMed Abstract available

SWAYZE EJ, Strzyzewski L, Avula P, Zebolsky AL, et al
The impact of expanding gynecologic oncology care to ovarian cancer patients in small cities and rural communities.
Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00331.
PubMed Abstract available

MARTINEZ A, Buckley M, Scalise CB, Katre AA, et al
Understanding the effect of mechanical forces on ovarian cancer progression.
Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00273.
PubMed Abstract available

ARTIOLI G, Giannone G, Valabrega G, Maggiorotto F, et al
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00324.
PubMed Abstract available

DENG M, Wu D, Zhang Y, Jin Z, et al
MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00323.
PubMed Abstract available

SHIM SH, Chae SH, So KA, Lee SJ, et al
Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer.
Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00270.
PubMed Abstract available

NITECKI R, Fleming ND, Fellman BM, Meyer LA, et al
Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00322.
PubMed Abstract available

GUPTA VG, Hirst J, Petersen S, Roby KF, et al
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00325.
PubMed Abstract available

TONE AA, McCuaig JM, Ricker N, Boghosian T, et al
The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
Gynecol Oncol. 2021 Apr 13. pii: S0090-8258(21)00321.
PubMed Abstract available

VAN DE VORST REWM, Hoogendam JP, van der Aa MA, Witteveen PO, et al
The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis.
Gynecol Oncol. 2021 Apr 10. pii: S0090-8258(21)00317.
PubMed Abstract available

FLEMING ND, Westin SN, Rauh-Hain JA, Soliman PT, et al
Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
Gynecol Oncol. 2021 Apr 7. pii: S0090-8258(21)00272.
PubMed Abstract available

CHASE DM, Neighbors J, Perhanidis J, Monk BJ, et al
Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay.
Gynecol Oncol. 2021 Apr 1. pii: S0090-8258(21)00259.
PubMed Abstract available

CRAMER DW, Vitonis AF, Sasamoto N, Yamamoto H, et al
Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).
Gynecol Oncol. 2021;161:282-290.
PubMed Abstract available

JOU J, Zimmer Z, Charo L, Yau C, et al
HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
Gynecol Oncol. 2021;161:25-33.
PubMed Abstract available

March 2021

MALLEN A, Todd S, Robertson SE, Kim J, et al
Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer.
Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00228.
PubMed Abstract available

RAFFONE A, Catena U, Travaglino A, Masciullo V, et al
Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00267.
PubMed Abstract available

GEOFFRON S, Lier A, de Kermadec E, Sermondade N, et al
Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG).
Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00268.
PubMed Abstract available

GIL-MORENO A, Alonso-Alconada L, Diaz-Feijoo B, Domingo S, et al
M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00260.
PubMed Abstract available

FALCONE F, Breda E, Ferrandina G, Malzoni M, et al
Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database.
Gynecol Oncol. 2021 Mar 26. pii: S0090-8258(21)00261.
PubMed Abstract available

CARTMEL B, Hughes M, Ercolano EA, Gottlieb L, et al
Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC).
Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00195.
PubMed Abstract available

FILIPPOVA OT, Tin AL, Alonso J, Vickers AJ, et al
Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00252.
PubMed Abstract available

ZHANG X, Devins K, Ko EM, Reyes MC, et al
Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00257.
PubMed Abstract available

NASIOUDIS D, Byrne M, Ko EM, Giuntoli RL 2nd, et al
Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma.
Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00256.
PubMed Abstract available

KONECNY GE, Oza AM, Tinker AV, Oaknin A, et al
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol. 2021 Mar 19. pii: S0090-8258(21)00235.
PubMed Abstract available

LOREEN A, Polen-De C, Monk BJ, Jackson AL, et al
The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00176.
PubMed

HASSELGREN E, Hertzberg D, Camderman T, Bjorne H, et al
Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00179.
PubMed Abstract available

ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Gynecol Oncol. 2021 Mar 11. pii: S0090-8258(21)00229.
PubMed Abstract available

MORDEN CR, Farrell AC, Sliwowski M, Lichtensztejn Z, et al
Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
Gynecol Oncol. 2021 Mar 10. pii: S0090-8258(21)00199.
PubMed Abstract available

LAGO V, Montero B, Lopez S, Padilla-Iserte P, et al
Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer.
Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00193.
PubMed Abstract available

BUECHEL ME, Enserro D, Burger RA, Brady MF, et al
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00177.
PubMed Abstract available

COWAN R, Nobre SP, Pradhan N, Yasukawa M, et al
Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00142.
PubMed Abstract available

BACKES FJ, Felix AS, Plante M, Gregoire J, et al
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
Gynecol Oncol. 2021 Mar 4. pii: S0090-8258(21)00154.
PubMed Abstract available

HUANG C, Lin X, He J, Liu N, et al
Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00169.
PubMed Abstract available

FILIPPOVA OT, Selenica P, Pareja F, Vahdatinia M, et al
Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00173.
PubMed Abstract available

AUBREY C, Saad N, Kobel M, Mattatall F, et al
Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status.
Gynecol Oncol. 2021 Mar 1. pii: S0090-8258(21)00158.
PubMed Abstract available

February 2021

SCHRIER E, Xiong N, Thompson E, Poort H, et al
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00168.
PubMed Abstract available

SJOQUIST KM, Espinoza D, Mileshkin L, Ananda S, et al
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00109.
PubMed Abstract available

AREND RC, Monk BJ, Herzog TJ, Moore KN, et al
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum r
Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00151.
PubMed Abstract available

DA CRUZ PAULA A, DeLair DF, Ferrando L, Fix DJ, et al
Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
Gynecol Oncol. 2021 Feb 20. pii: S0090-8258(21)00152.
PubMed Abstract available

KURTZ JE, Gebski V, Sukhin V, Carey M, et al
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecol Oncol. 2021 Feb 18. pii: S0090-8258(21)00155.
PubMed Abstract available

INCI MG, Anders L, Woopen H, Richter R, et al
Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study.
Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00149.
PubMed Abstract available

BAANDRUP L, Dehlendorff C, Hertzum-Larsen R, Hannibal CG, et al
Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer The Extreme study.
Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00102.
PubMed Abstract available

HICKEY M, Moss KM, Brand A, Wrede CD, et al
What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00108.
PubMed Abstract available

DAHM-KAHLER P, Holmberg E, Holtenman M, Radestad AF, et al
Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00059.
PubMed Abstract available

CHAMBERS LM, Yao M, Morton M, Gruner M, et al
Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00099.
PubMed Abstract available

RAHIMY E, Usoz M, von Eyben R, Fujimoto D, et al
Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.
Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00093.
PubMed Abstract available

LIU S, Kasherman L, Fazelzad R, Wang L, et al
The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00088.
PubMed Abstract available

January 2021

HARRISON RF, Cantor SB, Sun CC, Villanueva M, et al
Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00084.
PubMed Abstract available

PIZZOFERRATO AC, Klein M, Fauvet R, Durand C, et al
Pelvic floor disorders and sexuality in women with ovarian cancer: A systematic review.
Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(21)00086.
PubMed Abstract available

TOZZI R, Traill Z, Valenti G, Ferrari F, et al
A prospective study on the diagnostic pathway of patients with stage IIIC-IV ovarian cancer: Exploratory laparoscopy (EXL) + CT scan VS. CT scan.
Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00060.
PubMed Abstract available

KIM SR, Tone A, Kim RH, Cesari M, et al
Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
Gynecol Oncol. 2021 Jan 18. pii: S0090-8258(21)00002.
PubMed Abstract available

NOVIKOVA OV, Nosov VB, Panov VA, Novikova EG, et al
Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Gynecol Oncol. 2021 Jan 15. pii: S0090-8258(21)00001.
PubMed Abstract available

CASTLE PE, Locke A, Tergas AI, Befano B, et al
The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(21)00052.
PubMed Abstract available

SCHEEPERS ERM, de Rooij BH, Pijnenborg JMA, van Huis-Tanja LH, et al
Perceived social support in patients with endometrial or ovarian cancer: A secondary analysis from the ROGY care study.
Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(20)34246.
PubMed Abstract available

BILBAO M, Aikins JK, Ostrovsky O
Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications.
Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34248.
PubMed Abstract available

HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34255.
PubMed Abstract available

DELLINGER TH, Han ES
State of the Science: The role of HIPEC in the treatment of ovarian cancer.
Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34243.
PubMed

HEUS C, Smorenburg A, Stoker J, Rutten MJ, et al
Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.
Gynecol Oncol. 2021;160:187-192.
PubMed Abstract available

FADADU PP, Polen-De CL, McGree ME, Weaver AL, et al
Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
Gynecol Oncol. 2021;160:40-44.
PubMed Abstract available

December 2020

DUSKA LR, Krasner CN, O'Malley DM, Hays JL, et al
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34228.
PubMed Abstract available

BOERNER T, Walch HS, Nguyen B, Iasonos A, et al
Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
Gynecol Oncol. 2020 Dec 29. pii: S0090-8258(20)34225.
PubMed Abstract available

LIANG MI, Chen L, Hershman DL, Hillyer GC, et al
Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
Gynecol Oncol. 2020 Dec 27. pii: S0090-8258(20)34218.
PubMed Abstract available

GHEZELAYAGH TS, Pennington KP, Norquist BM, Khasnavis N, et al
Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34178.
PubMed Abstract available

PHILP L, Tannenbaum S, Haber H, Saini A, et al
Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34174.
PubMed Abstract available

GUO Y, Jiang T, Ouyang L, Li X, et al
A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses.
Gynecol Oncol. 2020 Dec 20. pii: S0090-8258(20)34177.
PubMed Abstract available

BANVILLE AC, Wouters MCA, Oberg AL, Goergen KM, et al
Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34176.
PubMed Abstract available

KARNEZIS AN, Chen SY, Chow C, Yang W, et al
Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
Gynecol Oncol. 2020 Dec 13. pii: S0090-8258(20)34175.
PubMed Abstract available

YUE H, Li W, Chen R, Wang J, et al
Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer.
Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34154.
PubMed Abstract available

GOTOH O, Kiyotani K, Chiba T, Sugiyama Y, et al
Immunogenomic landscape of gynecologic carcinosarcoma.
Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34158.
PubMed Abstract available

STOVER EH, Fuh K, Konstantinopoulos PA, Matulonis UA, et al
Clinical assays for assessment of homologous recombination DNA repair deficiency.
Gynecol Oncol. 2020;159:887-898.
PubMed Abstract available

WANG Z, Yin P, Sun Y, Na L, et al
LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
Gynecol Oncol. 2020;159:839-849.
PubMed Abstract available

FUH K, Mullen M, Blachut B, Stover E, et al
Homologous recombination deficiency real-time clinical assays, ready or not?
Gynecol Oncol. 2020;159:877-886.
PubMed Abstract available

VETTER MH, Castaneda A, Khan A, O'Malley DM, et al
A clinical classification system for grading platinum hypersensitivity reactions.
Gynecol Oncol. 2020;159:794-798.
PubMed Abstract available

November 2020

STRAUBHAR AM, Wolf JL, Zhou MQC, Iasonos A, et al
Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34132.
PubMed Abstract available

HULSTAERT E, Morlion A, Levanon K, Vandesompele J, et al
Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review.
Gynecol Oncol. 2020 Nov 27. pii: S0090-8258(20)34129.
PubMed Abstract available

WU L, Zhu J, Yin R, Wu X, et al
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
Gynecol Oncol. 2020 Nov 26. pii: S0090-8258(20)34013.
PubMed Abstract available

CONSIDINE DPC, Jia G, Shu X, Schildkraut JM, et al
Genetically predicted circulating protein biomarkers and ovarian cancer risk.
Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34127.
PubMed Abstract available

CHO A, Lee SW, Park JY, Kim DY, et al
Continued medical treatment for persistent early endometrial cancer in young women.
Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34115.
PubMed Abstract available

CHELARIU-RAICU A, Nick A, Urban R, Gordinier M, et al
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34124.
PubMed Abstract available

KHATIB G, Seyfettinoglu S, Guzel AB, Gulec UK, et al
Feasibility and rationale of a novel approach in advanced ovarian cancer surgery: Bat- shaped en-bloc total peritonectomy and total hysterectomy salpingo-oophorectomy with or without rectosigmoid resection (Sarta-Bat approach).
Gynecol Oncol. 2020 Nov 21. pii: S0090-8258(20)34122.
PubMed Abstract available

FEJZO MS, Chen HW, Anderson L, McDermott MS, et al
Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34116.
PubMed Abstract available

MORSE CB, Voillet V, Bates BM, Chiu EY, et al
Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.
Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34117.
PubMed Abstract available

RANA HQ, Kipnis L, Hehir K, Cronin A, et al
Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34111.
PubMed Abstract available

FREY MK, Chapman-Davis E, Glynn SM, Lin J, et al
Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic.
Gynecol Oncol. 2020 Nov 19. pii: S0090-8258(20)34128.
PubMed Abstract available

XU Y, Jia Y, Zhang Q, Du Y, et al
Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34121.
PubMed Abstract available

WEEKS K, Lynch CF, West M, Carnahan R, et al
Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients.
Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34114.
PubMed Abstract available

BOERNER T, Tanner E, Filippova O, Zhou QC, et al
Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34064.
PubMed Abstract available

O'TOOLE SA, Huang Y, Norris L, Power Foley M, et al
HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34112.
PubMed Abstract available

CHEN F, Bailey CE, Alvarez RD, Shu XO, et al
Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer.
Gynecol Oncol. 2020 Nov 15. pii: S0090-8258(20)34062.
PubMed Abstract available

POORT H, Fenton ATHR, Thompson E, Dinardo MM, et al
Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34056.
PubMed Abstract available

KIMBLE DC, Dvergsten E, Thomeas-McEwing V, Karovic S, et al
Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer.
Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34066.
PubMed Abstract available

WALL JA, Meza-Perez S, Scalise CB, Katre A, et al
Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34053.
PubMed Abstract available

WESLEY E, Uppendahl LD, Felices M, Dahl C, et al
Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34051.
PubMed Abstract available

BIZZARRI N, du Bois A, Fruscio R, De Felice F, et al
Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34050.
PubMed Abstract available

BLANC-DURAND F, Genestie C, Galende EY, Gouy S, et al
Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
Gynecol Oncol. 2020 Nov 5. pii: S0090-8258(20)33955.
PubMed Abstract available

RUSSELL B, Hawarden A, Gee M, Edmondson RJ, et al
Propensity score matching confirms that primary surgery or neoadjuvant chemotherapy result in equivalent survival within a comprehensive cohort of patients with high-grade serous ovarian cancer.
Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34057.
PubMed Abstract available

DIAZ-FEIJOO B, Bebia V, Hernandez A, Gilabert-Estalles J, et al
Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer.
Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34060.
PubMed Abstract available

October 2020

RUBINSTEIN MM, Grisham RN, Cadoo K, Kyi C, et al
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Gynecol Oncol. 2020 Oct 30. pii: S0090-8258(20)34041.
PubMed Abstract available

ELAYAPILLAI S, Ramraj S, Benbrook DM, Bieniasz M, et al
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34018.
PubMed Abstract available

MATSUO K, Matsuzaki S, Nusbaum DJ, Maoz A, et al
Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34049.
PubMed Abstract available

CEPPI L, Grassi T, Galli F, Buda A, et al
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34036.
PubMed Abstract available

HALL MR, Dehbi HM, Banerjee S, Lord R, et al
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)33958.
PubMed Abstract available

BARBER EL, Garg R, Persenaire C, Simon M, et al
Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
Gynecol Oncol. 2020 Oct 14. pii: S0090-8258(20)34012.
PubMed Abstract available

MORTON M, Chambers LM, Costales AB, Chichura A, et al
Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Gynecol Oncol. 2020 Oct 13. pii: S0090-8258(20)33962.
PubMed Abstract available

MICHELS J, Genestie C, Dunant A, Caron O, et al
Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33960.
PubMed Abstract available

HAUNSCHILD CE, Tewari KS
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
Gynecol Oncol. 2020 Oct 11. pii: S0090-8258(20)33953.
PubMed Abstract available

CARR C, Son J, Yao M, Priyadarshini A, et al
Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Gynecol Oncol. 2020 Oct 9. pii: S0090-8258(20)33949.
PubMed Abstract available

NICA A, Lee JYJ, Hong NL, May T, et al
Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
Gynecol Oncol. 2020 Oct 6. pii: S0090-8258(20)33961.
PubMed Abstract available

CORVIGNO S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, et al
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33951.
PubMed Abstract available

CICCONE MA, Adams CL, Bowen C, Thakur T, et al
Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33950.
PubMed Abstract available

UBACHS J, Koole SN, Lahaye M, Fabris C, et al
No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33952.
PubMed Abstract available

GERSHENSON DM, Cobb LP, Sun CC
Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors.
Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33959.
PubMed

LENTZ SE, Powell CB, Haque R, Armstrong MA, et al
Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
Gynecol Oncol. 2020 Oct 1. pii: S0090-8258(20)33914.
PubMed Abstract available

EAKIN CM, Ewongwo A, Pendleton L, Monk BJ, et al
Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
Gynecol Oncol. 2020;159:112-117.
PubMed Abstract available

SALANI R, Liu JF
Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical Oncology.
Gynecol Oncol. 2020;159:13-16.
PubMed

CRESTANI A, Benoit L, Touboul C, Pasquier J, et al
Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?
Gynecol Oncol. 2020;159:285-294.
PubMed Abstract available

September 2020

KOTSOPOULOS J, Gronwald J, McCuaig JM, Karlan BY, et al
Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33947.
PubMed Abstract available

CHAN JK, Liang SY, Kapp DS, Chan JE, et al
Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33910.
PubMed

LANDOLFO C, Achten ETL, Ceusters J, Baert T, et al
Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33918.
PubMed Abstract available

MIRZA MR, Benigno B, Dorum A, Mahner S, et al
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33899.
PubMed Abstract available

WICHMANN C, Klotz DM, Zeiler HJ, Hilger RA, et al
The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33911.
PubMed Abstract available

MANRRIQUEZ E, Mandelbaum A, Aguayo E, Zakhour M, et al
Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33919.
PubMed Abstract available

CHARO LM, Jou J, Binder P, Hohmann SF, et al
Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33915.
PubMed Abstract available

JOHNSON KE, Popratiloff A, Fan Y, McDonald S, et al
Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients.
Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33921.
PubMed Abstract available

EAKIN CM, Norton TJ, Monk BJ, Chase DM, et al
Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33817.
PubMed Abstract available

MUSORO JZ, Coens C, Greimel E, King MT, et al
Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33900.
PubMed Abstract available

WALLBILLICH JJ, Morris RT, Ali-Fehmi R
Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Gynecol Oncol. 2020 Sep 5. pii: S0090-8258(20)33813.
PubMed Abstract available

DI DONATO V, Di Pinto A, Giannini A, Caruso G, et al
Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
Gynecol Oncol. 2020 Sep 4. pii: S0090-8258(20)33823.
PubMed Abstract available

August 2020

SHEN L, Xie L, Li R, Shan B, et al
A preoperative prediction model for predicting coexisting adnexa malignancy of patients with G1/G2 endometrioid endometrial cancer.
Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33818.
PubMed Abstract available

BELL SG, Dalton L, McNeish BL, Fang F, et al
Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients.
Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33816.
PubMed Abstract available

BOERNER T, Filippova OT, Chi AJ, Iasonos A, et al
Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
Gynecol Oncol. 2020 Aug 10. pii: S0090-8258(20)33751.
PubMed Abstract available

July 2020

COLOMBO N, Oza AM, Lorusso D, Aghajanian C, et al
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)31130.
PubMed Abstract available

BLANC-DURAND F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, et al
Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)33654.
PubMed Abstract available

COBB LP, Sun CC, Iyer R, Nick AM, et al
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32324.
PubMed Abstract available

WEISS AS, Swisher E, Pennington KP, Radke M, et al
Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
Gynecol Oncol. 2020 Jul 21. pii: S0090-8258(20)32335.
PubMed Abstract available

MCCUAIG JM, Care M, Ferguson SE, Kim RH, et al
Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
Gynecol Oncol. 2020 Jul 13. pii: S0090-8258(20)32333.
PubMed Abstract available

PRESSEY JG, Dandoy CE, Pater LE, Sroga Rios J, et al
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)31975.
PubMed Abstract available

BERNARD L, Boucher J, Helpman L
Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study.
Gynecol Oncol. 2020 Jul 6. pii: S0090-8258(20)32330.
PubMed Abstract available

DERQUIN F, Floquet A, Hardy-Bessard AC, Edeline J, et al
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
Gynecol Oncol. 2020 Jul 2. pii: S0090-8258(20)32315.
PubMed Abstract available

BAE-JUMP V
Unraveling the mystery of clear cell endometrial cancer.
Gynecol Oncol. 2020;158:1-2.
PubMed

June 2020

SIMPSON AN, Sutradhar R, Ferguson SE, Robertson D, et al
Perioperative outcomes of women with and without class III obesity undergoing hysterectomy for endometrioid endometrial cancer: A population-based study.
Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32295.
PubMed Abstract available

MARIA S, Faron M, Maulard A, Pautier P, et al
Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32304.
PubMed Abstract available

PYRZAK A, Chen L, Kocherginsky M, Barber EL, et al
Radiation and hormonal therapy for primary treatment of stage I endometrial cancer and long-term survival.
Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31088.
PubMed Abstract available

MORRISON A, Nasioudis D
Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31121.
PubMed Abstract available

VENERIS JT, Mahajan P, Frazier AL
Contemporary management of ovarian germ cell tumors and remaining controversies.
Gynecol Oncol. 2020 Jun 4. pii: S0090-8258(20)31075.
PubMed Abstract available

CHEN H, Gotimer K, De Souza C, Tepper CG, et al
Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
Gynecol Oncol. 2020;157:783-792.
PubMed Abstract available

DUSKA LR, Petroni GR, Varhegyi N, Brown J, et al
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Gynecol Oncol. 2020;157:585-592.
PubMed Abstract available

May 2020

SMAZYNSKI J, Hamilton PT, Thornton S, Milne K, et al
The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Gynecol Oncol. 2020 May 20. pii: S0090-8258(20)30989.
PubMed Abstract available

DAI Y, Wang Z, Wang J
Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data.
Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)30984.
PubMed Abstract available

April 2020

NASIOUDIS D, Ko EM, Haggerty AF, Cory L, et al
Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
Gynecol Oncol. 2020 Apr 28. pii: S0090-8258(20)30306.
PubMed Abstract available

CHEVROT A, Pouget N, Bats AS, Huchon C, et al
Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
Gynecol Oncol. 2020;157:29-35.
PubMed Abstract available

SCOTT SA, Llaurado Fernandez M, Kim H, Elit L, et al
Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
Gynecol Oncol. 2020;157:36-45.
PubMed Abstract available

MUELLER JJ, Pedra Nobre S, Braxton K, Alektiar KM, et al
Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.
Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30250.
PubMed Abstract available

March 2020

RUSH SK, Swisher EM, Garcia RL, Pennington KP, et al
Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Gynecol Oncol. 2020 Mar 19. pii: S0090-8258(20)30101.
PubMed Abstract available

WOLFORD JE, Bai J, Moore KN, Kristeleit R, et al
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30176.
PubMed Abstract available

GONTHIER C, Douhnai D, Koskas M
Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer.
Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30157.
PubMed Abstract available

REINHOLDT K, Kjaer SK, Guleria S, Frederiksen K, et al
Risk of endometrial cancer among women with benign ovarian tumors - A Danish nationwide cohort study.
Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30178.
PubMed Abstract available

LENCK C, Chopin N, Gouy S, Bonsang-Kitzis H, et al
The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
Gynecol Oncol. 2020 Mar 1. pii: S0090-8258(20)30145.
PubMed Abstract available

February 2020

PLETT H, Harter P, Ataseven B, Heitz F, et al
Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors.
Gynecol Oncol. 2020 Feb 27. pii: S0090-8258(20)30102.
PubMed Abstract available

GLASER GE, Kalogera E, Kumar A, Yi J, et al
Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery.
Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30161.
PubMed Abstract available

PRAISS AM, Huang Y, St Clair CM, Tergas AI, et al
A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer.
Gynecol Oncol. 2020 Feb 21. pii: S0090-8258(20)30150.
PubMed Abstract available

UEHARA T, Yoshida H, Fukuhara M, Yoshida M, et al
Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites.
Gynecol Oncol. 2020 Feb 13. pii: S0090-8258(20)30099.
PubMed Abstract available

COLEMAN RL, Handley KF, Burger R, Molin GZD, et al
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30095.
PubMed Abstract available

ROJAS C, Tian C, Powell MA, Chan JK, et al
Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
Gynecol Oncol. 2020 Feb 3. pii: S0090-8258(20)30057.
PubMed Abstract available

January 2020

KORENAGA TR, Ward KK, Saenz C, McHale MT, et al
The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.
Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30086.
PubMed Abstract available

SIEMON J, Galli J, Slomovitz B, Schlumbrecht M, et al
Disparities in care among patients with low-grade serous ovarian carcinoma.
Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(19)31871.
PubMed Abstract available

NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
Trends in the surgical management of malignant ovarian germ-cell tumors.
Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30087.
PubMed Abstract available

BOGANI G, Ditto A, Lopez S, Bertolina F, et al
Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(19)31875.
PubMed Abstract available

NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
Primary malignant ovarian carcinoid; management and outcomes.
Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30002.
PubMed Abstract available

LLAURADO FERNANDEZ M, Dawson A, Kim H, Lam N, et al
Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(19)31680.
PubMed Abstract available

RAFFONE A, Travaglino A, Mascolo M, Carotenuto C, et al
Histopathological characterization of ProMisE molecular groups of endometrial cancer.
Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30008.
PubMed Abstract available

WANG D, Zhu S, Jia C, Cao D, et al
Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience.
Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(19)31872.
PubMed Abstract available

PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31870.
PubMed Abstract available

December 2019

CONNOR YD, Miao D, Lin DI, Hayne C, et al
Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
Gynecol Oncol. 2019 Dec 21. pii: S0090-8258(19)31618.
PubMed Abstract available

MATSUO K, Machida H, Matsuzaki S, Grubbs BH, et al
Evolving population-based statistics for rare epithelial ovarian cancers.
Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31781.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.